Evidence map›Paper›PMID 31530577›Full record

Trial reportJournal of the American Society of Nephrology : JASN2019

Effect of Canagliflozin on Renal and Cardiovascular Outcomes across Different Levels of Albuminuria: Data from the CANVAS Program.

Brendon L Neuen, Toshiaki Ohkuma, Bruce Neal, David R Matthews, Dick de Zeeuw, Kenneth W Mahaffey, Greg Fulcher, Qiang Li, Meg Jardine, Richard Oh and 2 more

Open access · hybridAbstract readMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of the American Society of Nephrology : JASN, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 65 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
65citing papers in PubMed, 6 pooled it
13.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

65 citing papers in PubMed, 6 syntheses or guidelines pooled it, 126 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Review
  17. Review
  18. Article
  19. The effects ofRenal failure · 2024
    Article
  20. Review

5 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 4 countries.

Brendon L NeuenThe George Institute for Global Health, University of New South Wales, Sydney, Australia.ORCID 0000-0001-9276-8380
Toshiaki OhkumaThe George Institute for Global Health, University of New South Wales, Sydney, Australia.
Bruce NealThe George Institute for Global Health, University of New South Wales, Sydney, Australia.
David R MatthewsOxford Centre for Diabetes, Endocrinology and Metabolism, Harris Manchester College, University of Oxford, Oxford, UK.
Dick de ZeeuwUniversity Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Kenneth W MahaffeyDepartment of Medicine, Stanford Center for Clinical Research, Stanford University School of Medicine, Stanford, California.
Greg FulcherRoyal North Shore Hospital, Sydney, Australia; and.
Qiang LiThe George Institute for Global Health, University of New South Wales, Sydney, Australia.
Meg JardineThe George Institute for Global Health, University of New South Wales, Sydney, Australia.
Richard OhJanssen Research & Development, LLC, Raritan, New Jersey.
Hiddo L HeerspinkThe George Institute for Global Health, University of New South Wales, Sydney, Australia.
Vlado PerkovicThe George Institute for Global Health, University of New South Wales, Sydney, Australia; vperkovic@georgeinstitute.org.au.
UNSW Sydney · AUUniversity Medical Center Groningen · NLJanssen (United States) · USRoyal North Shore Hospital · AUStanford Medicine · USUniversity of Oxford · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIf SGLT2 inhibitors protect the kidneys by reducing albuminuria as hypothesized, people with type 2 diabetes mellitus (T2DM) with higher albuminuria should benefit more.

methodsWe conducted a

resultsCanagliflozin lowered albuminuria with greater proportional reductions in those with moderately and severely increased albuminuria (

conclusionsThe proportional effects of canagliflozin on renal and cardiovascular outcomes are mostly consistent across patients with different levels of albuminuria, but absolute benefits are greatest among those with severely increased albuminuria.

Indexed as

AgedAlbuminuriaCanagliflozinCardiovascular SystemDiabetes Mellitus, Type 2FemaleGlomerular Filtration RateHumansMaleMiddle AgedSodium-Glucose Transporter 2 InhibitorsCanagliflozinSodium-Glucose Transporter 2 InhibitorsalbuminuriacanagliflozincardiovascularrenalSGLT2 inhibitor

Identifiers

PMID31530577
PMCPMC6830803
OpenAlexW2973242786

What OpenQuestion holds

Texttitle and abstract
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.